Patents by Inventor Qingwang LIU

Qingwang LIU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIHYDROISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AND USES THEREOF
    Publication number: 20230416221
    Abstract: A kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. A method and a use for using the inhibitor for treatment of diseases related to CDK9 and/or mutagenic activity thereof.
    Type: Application
    Filed: October 21, 2021
    Publication date: December 28, 2023
    Applicant: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES
    Inventors: Qingsong LIU, Jing LIU, Yun WU, Beilei WANG, Aoli WANG, Chen HU, Qingwang LIU, Fengming ZOU, Wenchao WANG, Zuowei WANG, Jiangyan CAO, Chenliang SHI, Li WANG
  • Pyrimidine derivative kinase inhibitors
    Patent number: 11602534
    Abstract: The present invention relates to a kinase inhibitor, comprising a compound of Formula I or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also relates to a pharmaceutical composition comprising the kinase inhibitor, and to uses and methods for using these compounds and compositions to inhibit the activity of wild-type FLT3, mutant FLT3-ITD, PDGFR? and/or PDGFR? kinase in a cell or a subject, as well as uses and methods of these compounds and compositions to preventing or treating kinase-associated conditions in a subject.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: March 14, 2023
    Assignee: Hefei Institutes of Physical Science, Chinese Academy of Sciences
    Inventors: Qingsong Liu, Jing Liu, Xiaofei Liang, Beilei Wang, Kailin Yu, Zongru Jiang, Cheng Chen, Chen Hu, Wenchao Wang, Fengming Zou, Qingwang Liu, Feng Li, Wenliang Wang, Li Wang
  • PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF
    Publication number: 20220064117
    Abstract: Disclosed are a kinase inhibitor and a pharmaceutical composition comprising the kinase inhibitor. The kinase inhibitor comprises a compound as represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug thereof. The compound and composition above can inhibit wild-type KIT and/or mutant KIT tyrosine kinase activity and treat, prevent, or alleviate diseases, disorders, or conditions associated with wild-type KIT and/or mutant KIT kinase activity.
    Type: Application
    Filed: December 20, 2018
    Publication date: March 3, 2022
    Applicant: Tarapeutics Science Inc.
    Inventors: Jing LIU, Qingsong LIU, Yun WU, Beilei WANG, ZiPing QI, Fengming ZOU, Qingwang LIU, Wenchao WANG, Cheng CHEN, Junjie WANG, Li WANG
  • SELECTIVE PI3Kdelta INHIBITOR AND USE THEREOF
    Publication number: 20220024931
    Abstract: The present application relates to a compound serving as a selective PI3K? kinase inhibitor, comprising the compound shown in formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof, wherein X, R1, R2, R3, R4, R5 and R6 are as defined in the description. The present application also relates to a method for using the kinase inhibitor to inhibit PI3K? kinase activity or to treat or prevent diseases or conditions associated with tyrosine kinase activity of PI3K?, as well as a use thereof.
    Type: Application
    Filed: December 12, 2018
    Publication date: January 27, 2022
    Applicant: TARAPEUTICS SCIENCE INC.
    Inventors: Qingsong LIU, Jing LIU, Xiaofei LIANG, Feng LI, Ziping QI, Zongru JIANG, Qingwang LIU, Kailin YU, Zhenquan HU, Beilei WANG, Li WANG
  • PYRIMIDINE DERIVATIVE KINASE INHIBITORS
    Publication number: 20200323850
    Abstract: The present invention relates to a kinase inhibitor, comprising a compound of Formula I or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also relates to a pharmaceutical composition comprising the kinase inhibitor, and to uses and methods for using these compounds and compositions to inhibit the activity of wild-type FLT3, mutant FLT3-ITD, PDGFR? and/or PDGFR? kinase in a cell or a subject, as well as uses and methods of these compounds and compositions to preventing or treating kinase-associated conditions in a subject.
    Type: Application
    Filed: December 26, 2017
    Publication date: October 15, 2020
    Applicant: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES
    Inventors: Qingsong LIU, Jing LIU, Xiaofei LIANG, Beilei WANG, Kailin YU, Zongru JIANG, Cheng CHEN, Chen HU, Wenchao WANG, Fengming ZOU, Qingwang LIU, Feng LI, Wenliang WANG, Li WANG